These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12950040)

  • 21. [Avian influenza pandemic prevention - current research].
    Nau JY
    Rev Med Suisse; 2006 Aug; 2(76):1939. PubMed ID: 16972546
    [No Abstract]   [Full Text] [Related]  

  • 22. [What do your patients want to know now? The most frequent questions about avian influenza].
    MMW Fortschr Med; 2006 Mar; 148(9):13. PubMed ID: 16566386
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pneumonia diagnosis in the practice on the test-bench: how much diagnosis is necessary?].
    Vogel GE
    Dtsch Med Wochenschr; 2002 Mar; 127(11):580; author reply 580.. PubMed ID: 11894183
    [No Abstract]   [Full Text] [Related]  

  • 24. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza.
    Hansen L
    Clin Evid; 2004 Dec; (12):1095-102. PubMed ID: 15865706
    [No Abstract]   [Full Text] [Related]  

  • 26. Influenza.
    Hansen L
    Clin Evid; 2003 Dec; (10):867-74. PubMed ID: 15555125
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of antiviral agents and other measures in an influenza pandemic.
    Groeneveld K; van der Noordaa J
    Neth J Med; 2005 Oct; 63(9):339-43. PubMed ID: 16244380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the best antiviral agent for influenza infection?
    Fagan HB; Moeller AH
    Am Fam Physician; 2004 Oct; 70(7):1331-2. PubMed ID: 15508545
    [No Abstract]   [Full Text] [Related]  

  • 29. [Strategies in the diagnosis and treatment of patients with avian influenza].
    Lin JT
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):355-6. PubMed ID: 15061981
    [No Abstract]   [Full Text] [Related]  

  • 30. A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses.
    Hurt AC; Barr IG; Komadina N; Hampson AW
    Virus Res; 2004 Jul; 103(1-2):79-83. PubMed ID: 15163493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zanamivir: an influenza virus neuraminidase inhibitor.
    Colman PM
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):191-9. PubMed ID: 15918777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiviral agents in influenza--current recommendations. Anti-influenza agents are not a substitution for but a complement to vaccination].
    Uhnoo I; Linde A
    Lakartidningen; 2005 Dec 5-11; 102(49):3802-3, 3805-6, 3808. PubMed ID: 16408704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptomatic predictors of influenza virus positivity in children during the influenza season.
    Ohmit SE; Monto AS
    Clin Infect Dis; 2006 Sep; 43(5):564-8. PubMed ID: 16886147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
    Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
    Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.
    Calfee DP; Peng AW; Hussey EK; Lobo M; Hayden FG
    Antivir Ther; 1999; 4(3):143-9. PubMed ID: 12731753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
    Cheam AL; Barr IG; Hampson AW; Mosse J; Hurt AC
    Antiviral Res; 2004 Sep; 63(3):177-81. PubMed ID: 15451185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cotton rat model of human parainfluenza 3 laryngotracheitis: virus growth, pathology, and therapy.
    Ottolini MG; Porter DD; Blanco JC; Prince GA
    J Infect Dis; 2002 Dec; 186(12):1713-7. PubMed ID: 12447755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
    Chand P; Bantia S; Kotian PL; El-Kattan Y; Lin TH; Babu YS
    Bioorg Med Chem; 2005 Jun; 13(12):4071-7. PubMed ID: 15911320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.